What should next-generation analytical platforms for biopharmaceutical production look like?

Trends Biotechnol. 2023 Sep 27:S0167-7799(23)00256-1. doi: 10.1016/j.tibtech.2023.08.008. Online ahead of print.ABSTRACTBiotherapeutic products, particularly complex products such as monoclonal antibodies (mAbs), have as many as 20-30 critical quality attributes (CQAs), thereby requiring a collection of orthogonal, high-resolution analytical tools for characterization and making characterization a resource-intensive task. As discussed in this Opinion, the need to reduce the cost of developing biotherapeutic products and the need to adopt Industry 4.0 and eventually Industry 5.0 paradigms are driving a reappraisal of existing analytical platforms. Next-generation platforms will have reduced offline testing, renewed focus on online testing and real-time monitoring, multiattribute monitoring, and extensive use of advanced data analytics and automation. They will be more complex, more sensitive, resource lean, and more responsive compared with existing platforms.PMID:37775418 | DOI:10.1016/j.tibtech.2023.08.008

Source: Trends in Biotechnology - September 29, 2023 Category: Biotechnology Authors: Anurag S Rathore Deepika Sarin Source Type: research